Exact Sciences Corp
EXAS
View Detailed Chart
103.180USD
+0.520+0.51%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
19.55BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.51%
5 Days
+0.82%
1 Month
+1.51%
6 Months
+119.95%
Year to Date
+1.60%
1 Year
+90.09%
View Detailed Chart
TradingKey Stock Score of Exact Sciences Corp
Currency: USD Updated: 2026-02-06Key Insights
Exact Sciences Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 72 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 101.83.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Exact Sciences Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Exact Sciences Corp Highlights
StrengthsRisks
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 32.37% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.76B.
Fairly Valued
The company’s latest PE is -19.32, at a medium 3-year percentile range.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 2.35K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.52.
Analyst Rating
Based on
23
analysts
Hold
Current Rating
101.833
Target Price
-0.81%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Exact Sciences Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Exact Sciences Corp Info
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Ticker SymbolEXAS
CompanyExact Sciences Corp
CEOConroy (Kevin T)
Websitehttps://www.exactsciences.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68832.830
-1137.300 (-1.63%)
282.580
+22.390 (+8.61%)
2036.020
-15.710 (-0.77%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
